85275-46-3

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-3-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its ability to be easily modified and incorporated into complex molecular structures. The BOC protecting group ensures that the nitrogen atom remains unreactive during initial stages of synthesis, allowing for selective reactions at the toluene-4-sulfonate ester.
Used in Organic Synthesis:
In the field of organic synthesis, 1-BOC-3-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE serves as a versatile building block for the creation of diverse organic molecules. Its functional groups enable chemists to perform selective reactions, leading to the formation of a wide range of compounds with potential applications in various industries.
Used in Research and Development:
1-BOC-3-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE is utilized in research and development settings for the exploration of new chemical reactions and the synthesis of novel compounds. Its unique structure and reactivity make it an attractive candidate for studying reaction mechanisms and developing new synthetic methodologies.
Overall, 1-BOC-3-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE's role in the synthesis of pharmaceuticals, its utility in organic chemistry, and its application in research and development highlight its importance as a building block in the creation of new and innovative compounds.

Upstream product

• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 98-59-9 p-toluenesulfonyl chloride 
• 14813-01-5 1-benzyl-3-hydroxypiperidine 
• 143900-43-0 tert-butyl (3R)-3-hydroxypiperidine-1-carboxylate 
• 940890-90-4 (S)-3-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester 
• 91599-79-0 (S)-1-N-benzyl-3-hydroxypiperidine 
• 91599-81-4 (R)-N-benzyl-3-hydroxypiperidine 
• 404577-34-0 (R)-3-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 143900-44-1 tert-butyl (3S)-3-hydroxypiperidine-1-carboxylate 

Downstream Products

• 1612774-51-2 (R)-tert-butyl 3-(5-amino-4-carbamoyl-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1558038-42-8 (R)-5-amino-3-(4-phenoxyphenyl)-1-piperidin-3-yl-1H-pyrazole-4-carboxylic acid amide 
• 1642571-07-0 (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dihydrochloride 
• 1612774-53-4 (R)-tert-butyl 3-(3-amino-4-cyano-5-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-50-1 (R)-tert-butyl 3-(5-amino-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-15-8 (R)-1-(1-acryloylpiperidin-3-yl)-3-amino-5-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide 
• 1612774-55-6 (R)-3-amino-5-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazole-4-carboxamide 
• 1612774-54-5 (R)-tert-butyl 3-(3-amino-4-carbamoyl-5-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-47-6 tert-butyl 3-(5-amino-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)-piperidine-1-carboxylate 
• 1612773-99-5 1-(1-acryloylpiperidin-3-yl)-5-(methylamino)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide 
• 1612777-08-8 tert-butyl 3-(5-(tert-butoxycarbonyl(methyl)amino)-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-48-7 tert-butyl 3-(5-(tert-butoxycarbonylamino)-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-21-6 5-amino-3-(4-phenoxyphenyl)-1-(1-(vinylsulfonyl)piperidin-3-yl)-1H-pyrazole-4-carboxamide 
• 1612774-23-8 (E)-5-amino-1-(1-(4-(dimethylamino)but-2-enoyl)piperidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide 

Relevant academic research and scientific papers

PROTEIN DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

SMARCA DEGRADERS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/o

Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor

The identification and lead optimization of a series of pyrazolo[3,4-d]pyridazinone derivatives are described as a novel class of potent irreversible BTK inhibitors, resulting in the discovery of compound 8. Compound 8 exhibited high potency against BTK kinase and acceptable PK profile. Furthermore, compound 8 demonstrated significant in vivo efficacy in a mouse-collagen-induced arthritis (CIA) model.

BENZOSULFONYL COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor

Therapeutic combinations of a proteasome inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a proteasome inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

A N - propylene carbonyl piperidine derivatives for the preparation of

The invention relates to a method for preparing an N-propylene carbonyl piperidine derivative, in particular to a new midbody for preparing ibrutinib, a preparation method of the new midbody and a method for preparing the ibrutinib, and belongs to the technical field of pharmacy. The method relates to a reaction as specified in the following formula (please see the specification for the formula). The method is easy to operate, capable of lowering cost and beneficial to industrial production.

Methods of Using BTK Inhibitors to Treat Dermatoses

In certain embodiments, the invention includes therapeutic methods of using a BTK inhibitor to treat dermatoses, such as psoriasis, atopic dermatitis, contact dermatitis, scleroderma, and cutaneous lupus erythematosus. In other embodiments, the methods of the invention further comprise the step of administering a therapeutically effective dose of an anti-inflammatory agent.

INHIBITOR OF BRUTON'S TYROSINE KINASE

Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers.

THERAPEUTIC COMBINATIONS OF A CD19 INHIBITOR AND A BTK INHIBITOR

Therapeutic combinations of a CD 19 inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a CD 19 inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer, such as a hematological malignancy. A combination of a BTK inhibitor and a CD 19 inhibitor, such as a CD19-targeted antibody or a CD19-targeted chimeric antigen receptor expressing T cell or NK cell, and compositions and uses thereof are disclosed. Combinations of a BTK inhibitor and a CD 19 inhibitor with a programmed death- 1 (PD-1) or PD-1 ligand (PD-L1) inhibitor and compositions and uses thereof are also disclosed.

Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor

Therapeutic combinations of an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of an IRAK4 inhibitor and a BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.